Analysts Set OnKure Therapeutics, Inc. (NASDAQ:OKUR) PT at $32.00

Shares of OnKure Therapeutics, Inc. (NASDAQ:OKUR) have been given an average rating of “Hold” by the five analysts that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $32.00.

A number of equities research analysts recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of OnKure Therapeutics in a report on Monday, December 22nd. Wall Street Zen raised OnKure Therapeutics to a “sell” rating in a research note on Saturday, November 1st.

Institutional Trading of OnKure Therapeutics

Several institutional investors have recently made changes to their positions in OKUR. XTX Topco Ltd bought a new position in shares of OnKure Therapeutics during the second quarter valued at about $25,000. Bailard Inc. bought a new position in shares of OnKure Therapeutics during the 2nd quarter worth approximately $34,000. Jane Street Group LLC purchased a new position in shares of OnKure Therapeutics in the 4th quarter worth approximately $56,000. Rangeley Capital LLC bought a new position in shares of OnKure Therapeutics in the second quarter valued at approximately $71,000. Finally, Barclays PLC increased its position in shares of OnKure Therapeutics by 4,286.8% during the fourth quarter. Barclays PLC now owns 27,242 shares of the company’s stock valued at $79,000 after acquiring an additional 26,621 shares during the last quarter. Institutional investors own 90.98% of the company’s stock.

OnKure Therapeutics Trading Up 0.4%

Shares of OKUR stock opened at $2.42 on Tuesday. The firm has a fifty day simple moving average of $2.85 and a two-hundred day simple moving average of $2.80. OnKure Therapeutics has a 12 month low of $1.70 and a 12 month high of $6.18. The firm has a market capitalization of $32.79 million, a PE ratio of -0.51 and a beta of 0.46.

About OnKure Therapeutics

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.